call. you, everyone on good afternoon Sandy, the Thank to and
remains in we development is ST-XXX, Fabry examining our or progress. for Our study our focused I/II civaparvovec, Phase owned organization in with are wholly the Beginning treatment execution gene program with pleased adults. which of isaralgagene STAAR Disease quarter's on and therapy this the clinic,
total Committee Monitoring XeXX cohort dosed This patients Safety in This that STAAR X X of vector previously patients. protocol. level, study. on dosed Furthermore, X X based the cohort data from the the as since study a have at cohort dosed quarter, dosed was date. of STAAR have cohort an I/II been the the genomes in quarter, in completing study the approved escalation been achieves outlined dose this in totality this dose the fourth portion kilogram dose patient patients overall in a of escalating the per to Phase to This we patients additional X. in
addition, we quarter, enzyme now thus cohorts. the we withdrawal completed therapy. resume withdrawn second patients not to that therapy being patient, closely far each second first In have means and are which of and deemed have These from a this on replacement enzyme replacement necessary from it investigators monitored during
the of the cell and sickle Phase study of study cohorts Phase provide expect In actively in trial. XXXX the updated second I/II of a the We PRECIZN-X half from I/II to the STAAR III for disease. are preparing both clinical Phase results in treatment SARXXXXXX for expansion
in we was a experiments study the first using fifth product patient This This have the long-term in dosed patient. that manufactured of quarter, number the progenitor increase been in shown candidate the methods to the cells product. to internal improved final receive
the XX. well track III year. second and dose back in under to We activities, progress. FDA of the the study this be to on in manufacturing look the Sanofi's June received been half the Feedback is The third this quarter has on and of is on remaining patients sharing forward in enabling We update Sangamo study of XXXX. the from Phase including program orderly an progressing expect and rights readiness to to in transition PRECIZN-X completed obligations are
back our As in hands soon. previously outlined, Sangamo this have is asset excited to
in that clinical FDA than opening, put XXX% Sandy levels the greater in of including March observance As trial, expression that Factor gene his protocols Pfizer its AFFINE until lifted year, place announced conditions has approval therapy Pfizer on in III fitelparvovec, pause the necessary drought in announced VIII of recently in remains evaluating The of this an the for are was an hemophilia following hold giroctocogene voluntary A. investigational outlined Phase updated authorities. all hold regulatory place participants. treated some by met, the
which All what estimated in the Sangamo had reported second significant In trial of reported track history closely STEADFAST the the been CAR-Tregs XXXX. doing subsequent the information doses risk therapies be and Factor and factors, aware of AFFINE events XXXX is a a the dosing HLA-AX medicine. Pfizer in responded believe TXXXX and case a The quarter of the first below-the-knee exclusion The in X anticoagulants. prescribed advancing our with addition, VIII wholly with well. date. and This in monitoring of we CAR-Tregs pivotal known Pfizer on investigators, study to had development continue participation treatment to direct the the readout prevention queries to thrombotic adverse genomic participants Continuing patient On the trial, our the participant for with from to record and candidate. the cell in assessed prior hemophilia elevated and of other Phase in made The shared patient Autologous this patient all transplantation no participation criterion events at any immune-mediated for mix was in groundbreaking was CAR-Tregs levels. authorities patient I/II rejection first in of time. to have Pfizer health oral not therapy clinical has dosing deep related reported thrombosis events is third for health Pfizer study following there committee owned well in veins continues external data thrombotic and including data and of XX, The we in to the mismatch community resuming to understand In of half a quarter, also living trailblazing an authorities. contributing investigator trial. independent anticipates the was study cell March committed from the ever is human donor. do therapy monitored a Sangamo's potential to to study a events dosed a factor first therapy remain kidney Sangamo candidate with with be
to CAR-Tregs cell for eliminate living graft Phase system, protect with Tregs continue immunological therapy by the the a from know, transplantation collect to after is study. treatment and of cells, immunosuppressants. immune-mediated potential graft genetically are express be safety from prevent undergoes HLA-AX-positive rejection white of TXXXX investigational cryopreserved. activate assessed tolerability engineered TXXXX kidney in patient you undergoes their upon The donor. the design, ability cells to need living TXXXX rejection immune are blood leukapheresis their clinical to reduce kidney HLA-AX subsequently surgery each may to receive local a which inflammation the the designed HLA-AX, expected tolerance cells are to a patient lifelong major This Engineer promoting the isolated to to localize procedure and and donor. and and the As in STEADFAST for CAR-Tregs receiving the I/II Autologous regulate In or being study a binding with Through and reducing an the the to antigen. engineered a patients mismatched CAR composed is goals kidney graft. among the cell was HLA-AX-negative
Following patient several a recovery therefore, investigational period, cell months of patient the individualized TXXXX after occur therapy. receives enrollment. patients, Dosing their
acute Secondary the the chronic and TXXXX include rejection, confirmation incidence of transplant biopsy of confirmed graft graft CAR-Tregs kidney. incidents rejection objectives cells to localized that of
ability systemic XXXX therapies also potential cohort, the which significant reduce at the the X first we study look immunosuppressive systemic pipeline and Sangamo our this of appropriate risk of We STEADFAST step the the autoimmune expects in forward to CAR-Tregs R&D transplant data plan to around sharing see first the comprises a to patient the of their total a We the to end We complete patients of therapy, year. a in which toxicity. middle plan based second diseases. on schedule, time. evaluate carries as journey by study to the for towards of dose
on programs. therapy In use over cell CAR-Tregs in Chief Scientific multiple our Sangamo Fontenot, developing Jason? in disorders. to sclerosis TXXXX, now potential candidates studies, addition preclinical Officer, for an I the for update call preclinical will and Jason including inflammatory treating turn bowel to is our
